Research use only, not for human consumption. Email [email protected]
← Research status explorer
Rebuild / Repair & longevity

BPC-157

Current research status Preclinical
Predominantly preclinical research
Preclinical

What is it?

BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) that is described in the literature as a partial sequence of a protein fraction isolated from human gastric juice. It was first studied for protection of the gastrointestinal lining and has since been investigated in laboratory models of tendon, ligament, muscle, nerve, skin and vascular injury. It is an investigational compound, and nearly all of the published data come from animal and cell-culture experiments.

Research overview

BPC-157 is a synthetic peptide derived from a fragment of a protein found in gastric juice, studied largely in rodent models of tissue repair, gut healing and tendon/ligament injury. No completed human clinical trials for BPC-157 were identified in public trial registries at the time of writing — the human evidence base is currently anecdotal rather than controlled.

Mechanism of action

The mechanisms of BPC-157 are proposed rather than established. In cultured rat tendon fibroblasts, BPC-157 was reported to increase cell outgrowth from tendon explants, survival under oxidative stress and cell migration, together with increased phosphorylation of the signalling proteins FAK and paxillin [PMID 21030672]. The same cell type showed increased expression of the growth hormone receptor after BPC-157 exposure, which the authors suggested could make the cells more responsive to growth hormone [PMID 25415472]. These are cell-culture findings and have not been shown to explain any effect in people.

Several reports link BPC-157 to blood-vessel biology. In chick membrane, endothelial cell and rat hind-limb ischaemia experiments, BPC-157 was reported to increase vessel density and to be associated with increased VEGFR2 expression and activation of a VEGFR2-Akt-eNOS signalling pathway [PMID 27847966]. In isolated rat aorta, BPC-157 was reported to relax vessels in an endothelium-dependent and nitric oxide-dependent way, with involvement of a Src-caveolin-1-eNOS pathway in cell experiments [PMID 33051481]. A 2026 ex vivo study of human arterial rings reported a similar endothelium-dependent, nitric oxide-related relaxation, and its authors describe this as early mechanistic evidence that needs further work [PMID 42123221].

Some of the older rodent tendon studies report effects on tendon healing together with changes in collagen, fibroblast and vascular appearance, but they do not identify a single receptor or pathway responsible [PMID 14554208]. A receptor for BPC-157 has not been identified in the records reviewed, and none of these mechanisms has been confirmed in controlled human studies.

Adult human evidence

Published human data on BPC-157 are very limited. A 2026 PRISMA-registered systematic review searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to June 2026 and included only three human studies (30 participants in total). None was a randomised controlled trial, all were judged to be of poor methodological quality, and the overall certainty of evidence was rated very low [PMID 42885452]. A 2025 narrative review likewise describes the human data as three pilot studies and states that rigorous, large-scale trials are lacking [PMID 40789979].

One small study (two participants) tested the safety of intravenous BPC-157 in two adults, aged 58 and 68 years, at a private clinic in Florida. Blood biomarkers of heart, liver, kidney, thyroid and glucose were reported to be unchanged, and no side effects were reported. With two participants, no control group and a three-day observation window, it cannot establish safety in a wider population or over longer periods [PMID 40131143].

A second pilot study followed twelve adult women (aged 39 to 76 years) with interstitial cystitis who had not responded to pentosan polysulfate. Each had a single procedure in which a compounded (503A pharmacy) BPC-157 preparation was injected around the area of bladder inflammation. All twelve rated their response at 80 percent or more on a global response questionnaire, and no adverse events were reported. The abstract describes no control group or blinding, the outcome was self-reported, and the product came from a compounding pharmacy, so these results cannot be separated from placebo or natural fluctuation of symptoms [PMID 39325560].

A retrospective chart review of intra-articular injections for knee pain has also been published. The ages of the participants are not stated in the available record, so it is not counted as adult evidence here; the systematic review above did include it among the three human studies. Separately, a 2026 laboratory study used residual arterial tissue from twelve adults undergoing coronary bypass surgery; this is ex vivo tissue work, not a clinical trial [PMID 42123221]. Registry entries for planned or ongoing controlled studies are described under research status.

Preclinical evidence

Most of the evidence for BPC-157 comes from rodent models. In rats with a surgically transected Achilles tendon, daily intraperitoneal BPC-157 was reported to improve functional, biomechanical, microscopic and macroscopic outcomes compared with saline controls, and to counteract the inhibitory effect of the aldehyde 4-hydroxynonenal on cultured tendon cells [PMID 14554208]. This and several other animal studies on tendon, ligament, muscle, spinal cord and gastrointestinal injury share a senior author, so independent replication in other laboratories matters for interpreting them.

Cell and tissue experiments from other groups report effects on tendon fibroblast migration and survival [PMID 21030672], on endothelial signalling and vessel formation in rats and chick membranes [PMID 27847966], and on vessel relaxation in isolated rat aorta [PMID 33051481]. These support the proposed biological activity but are short-term, mostly in vitro experiments.

A formal pharmacokinetic study in rats and beagle dogs reported that intact BPC-157 had a plasma elimination half-life of under 30 minutes, that intramuscular bioavailability was roughly 14 to 19 percent in rats and 45 to 51 percent in dogs, and that the peptide was broken down quickly into small peptide fragments and amino acids. Human pharmacokinetics were not part of that study [PMID 36588717].

A 2026 critical review of rodent ischaemia-reperfusion studies concluded that the findings are heterogeneous and often rely on short observation periods and single-dose designs, with incompletely characterised risk of bias, and that BPC-157 should be seen as a hypothesis-generating candidate for further preclinical research rather than an established therapy [PMID 42794771].

Evidence limitations

  • No completed, published randomised controlled trial in humans was identified; the three published human studies total about 30 participants, are uncontrolled and were rated very low certainty.
  • Most of the evidence is from rodent and cell-culture experiments, and results in animals frequently do not carry over to people.
  • Many animal studies share one senior author or group, with limited independent replication, and published critical reviews note short observation periods and unclear risk of bias.
  • Route of administration, timing and amounts vary widely between studies, so results cannot be compared directly or applied to other settings.
  • Human pharmacokinetics and long-term safety have not been characterised; the only human safety data are from two participants over a short period.
  • Product quality is a concern: reviews note unregulated manufacturing and contamination risk, and the human pilot data used compounded preparations rather than a standardised pharmaceutical product.
  • The proposed mechanisms (VEGFR2 and nitric oxide signalling, growth hormone receptor expression, FAK-paxillin) come largely from cell and animal experiments and no receptor has been identified.

Research and regulatory status

BPC-157 is described in the reviews checked as an investigational peptide without regulatory approval for human use, with no approved formulation and no completed Phase II trial [PMID 42885452] [PMID 42198317]. A ClinicalTrials.gov search (checked 2026-11-20) found a Phase 1 safety and pharmacokinetics study of an oral preparation in healthy volunteers (NCT02637284, status listed as unknown), a Phase 2 randomised placebo-controlled study in acute hamstring strain (NCT07437547, recruiting) and a pilot randomised study after rotator cuff repair (NCT07803250, not yet recruiting). No published results from these registered studies were identified in the sources checked.

Key studies

Review

Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety.

Poolton JT, Minett J, Kazmi A · Acta orthopaedica Belgica · 2026

Design
Systematic review (PRISMA, PROSPERO-registered)
Participants / model
Human studies of BPC-157 for any indication
Sample size
3 studies, 30 participants in total
Principal findings
Three small human studies met inclusion (knee pain, interstitial cystitis, intravenous safety). All reported symptom improvement in most participants without treatment-related adverse events, but were judged to be of poor methodological quality, and overall certainty of evidence was rated very low.
Limitations
The review can only be as strong as its included studies, which were uncontrolled, very small and at serious risk of bias. The authors conclude BPC-157 should not be used clinically outside regulated, high-quality trials.

PubMed 42885452 DOI 10.52628/92.3.15837

Review

BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.

Demirtaş H · International journal of molecular sciences · 2026

Design
Critical review of preclinical studies (no meta-analysis)
Participants / model
Rodent ischaemia-reperfusion injury models
Sample size
not stated in the abstract
Principal findings
Across rodent studies, BPC 157 was associated with attenuated oxidative injury, modulation of nitric oxide-related vascular responses and reduced inflammatory and apoptotic markers. The author concludes the evidence supports BPC 157 as a hypothesis-generating investigational candidate rather than an established therapy.
Limitations
The review notes heterogeneous models, short observation periods, single-dose designs and incompletely characterised risk of bias; no meta-analysis was possible.

PubMed 42794771 DOI 10.3390/ijms27188344

Adult human study

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

Lee E, Burgess K · Alternative therapies in health and medicine · 2025

Design
Pilot safety study, IRB-approved, uncontrolled
Participants / model
Two adults (a 58-year-old man and a 68-year-old woman) at a private clinic in Florida, each of whom had previously received intravenous BPC-157
Sample size
2 participants
Principal findings
Over three days, infusions were reported to cause no measurable change in the tested biomarkers of heart, liver, kidney, thyroid or blood glucose, and no side effects were reported.
Limitations
Only two participants, no control group and a very short follow-up, so the study cannot show safety in a broader population; both participants had prior exposure.

PubMed 40131143

Adult human study

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.

Lee E, Walker C, Ayadi B · Alternative therapies in health and medicine · 2024

Design
Uncontrolled pilot study at a private clinic
Participants / model
Adult women (aged 39 to 76 years) with interstitial cystitis who had not responded to pentosan polysulfate; compounded (503A pharmacy) BPC-157
Sample size
12 women
Principal findings
All twelve patients rated their response at 80 percent or more on a Global Response Assessment questionnaire (ten reported complete symptom resolution), and no adverse events were reported.
Limitations
Small, uncontrolled, self-reported outcomes with no stated blinding, using a compounded product; placebo response and natural symptom variation cannot be excluded.

PubMed 39325560

Preclinical (animal / cell)

Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.

Staresinic M, Sebecic B, Patrlj L, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003

Design
Rat tendon transection model plus cultured tendon cells
Participants / model
Rats with transected Achilles tendon (saline-treated controls) and cultured tendocytes
Sample size
not stated in the abstract
Principal findings
BPC 157-treated rats were reported to show higher load to failure, better functional index scores and more organised tendon repair on microscopy than controls. In cultured tendocytes, BPC 157 opposed the growth-inhibiting effect of 4-hydroxynonenal.
Limitations
Rat model with systemic administration soon after surgery; sample size is not stated in the abstract and the work comes from one research group.

PubMed 14554208 DOI 10.1016/S0736-0266(03)00110-4

Preclinical (animal / cell)

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.

Chang CH, Tsai WC, Lin MS, et al. · Journal of applied physiology (Bethesda, Md. : 1985) · 2011

Design
In vitro and ex vivo cell and explant experiments
Participants / model
Rat Achilles tendon explants and tendon fibroblasts
Sample size
not stated in the abstract
Principal findings
BPC 157 accelerated outgrowth of fibroblasts from tendon explants, increased cell survival under hydrogen peroxide stress and increased fibroblast migration. FAK and paxillin phosphorylation increased, which the authors propose as the mediating pathway; direct effects on proliferation were not seen.
Limitations
Cell culture and explant work, so effects in living tendon and in humans are not shown; the proposed FAK-paxillin pathway is correlative.

PubMed 21030672 DOI 10.1152/japplphysiol.00945.2010

Preclinical (animal / cell)

Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.

Hsieh MJ, Liu HT, Wang CN, et al. · Journal of molecular medicine (Berlin, Germany) · 2017

Design
Chick chorioallantoic membrane assay, endothelial cell culture and rat hind-limb ischaemia model
Participants / model
Chick embryo membrane, human vascular endothelial cells and rats with hind-limb ischaemia
Sample size
not stated in the abstract
Principal findings
BPC 157 was reported to increase vessel density, accelerate blood-flow recovery in ischaemic rat hind limb and increase VEGFR2 expression, with activation of a VEGFR2-Akt-eNOS signalling pathway in endothelial cells.
Limitations
Mechanistic findings are mostly cell-based or in short animal models; the dependence on VEGFR2 was inferred from inhibitor and expression data rather than confirmed in humans.

PubMed 27847966 DOI 10.1007/s00109-016-1488-y

Preclinical (animal / cell)

Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway.

Hsieh MJ, Lee CH, Chueh HY, et al. · Scientific reports · 2020

Design
Isolated tissue and cell experiments
Participants / model
Isolated rat aorta rings, vascular smooth muscle and endothelial cell cultures
Sample size
not stated in the abstract
Principal findings
BPC 157 produced concentration-dependent, endothelium-dependent and nitric oxide-dependent relaxation of rat aorta, and increased phosphorylation of Src, caveolin-1 and eNOS in endothelial cells.
Limitations
Isolated-tissue and in vitro work; the relevance of these concentrations and pathways to living animals or people is not established.

PubMed 33051481 DOI 10.1038/s41598-020-74022-y

Preclinical (animal / cell)

Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.

He L, Feng D, Guo H, et al. · Frontiers in pharmacology · 2022

Design
Pharmacokinetic, excretion and tissue distribution study including radiolabelled peptide
Participants / model
Rats and beagle dogs
Sample size
not stated in the abstract
Principal findings
The elimination half-life of intact BPC157 was under 30 minutes with linear kinetics; intramuscular bioavailability was about 14-19% in rats and 45-51% in dogs. The peptide was reported to be rapidly broken down into small fragments and amino acids, with excretion via urine and bile.
Limitations
Two animal species only; human pharmacokinetics are not addressed, and the abstract does not give group sizes.

PubMed 36588717 DOI 10.3389/fphar.2022.1026182

Preclinical (animal / cell)

Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.

Yildirim AK, Dastan AO, Demeli Ertus M, et al. · Journal of clinical medicine · 2026

Design
Ex vivo organ-bath study of human arterial rings (laboratory study, not a clinical trial)
Participants / model
Residual internal mammary artery segments from adults undergoing elective coronary artery bypass surgery
Sample size
12 patients' tissue segments
Principal findings
BPC 157 produced a concentration-dependent reduction in phenylephrine-induced contraction, greater in endothelium-intact rings, and the effect was attenuated by the nitric oxide synthase inhibitor L-NAME.
Limitations
Ex vivo tissue from a surgical population, with no measurement of effects in living people; the authors state further molecular and in vivo studies are required to clarify clinical relevance.

PubMed 42123221 DOI 10.3390/jcm15093488

Last reviewed: 20 November 2026